gdc
Neuroendocrine Tumors

Drugs for Neuroendocrine Tumors (NETs)

Here are the financial support services available to patients receiving treatment for Neuroendocrine Tumors (NETs).

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-pay Card

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Afinitor for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Afinitor for free for 1 year, or until a prescription drug coverage becomes available to them.

Somatuline Depot (lanreotide) Injection

Drug company: Ipsen
866-435-5677

Somatuline Depot is a somatostatin analog used for the treatment of patients with unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic neuroendocrine tumors (NETs) of gastrointestinal or pancreatic origin.

IPSEN CARES offers 2 financial assistance programs for patients using Somatuline Depot:

Somatuline Depot Virtual Copay Savings Program

Eligible patients with private insurance pay no more than $5 per prescription with this program for 12 months, 13 injections, or for a maximum copay benefit of $20,000 (whichever comes first). Patients with no insurance, or those whose insurance does not cover Somatuline Depot, may pay more than $5 per prescription and their maximum copay benefit amount for prescriptions is $1,666.66, up to an annual maximum of $20,000.

Somatuline Depot Patient Assistance Program

Eligible patients who are experiencing financial hardship, or who have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.

Sutent (sunitinib malate) Capsules

Drug company: Pfizer
877-744-5675

Sutent is a kinase inhibitor used for the treatment of patients with locally advanced or metastatic pancreatic neuroendocrine tumors (NETs) that have progressed and cannot be removed by surgery.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Sutent for free.

Carcinoid Syndrome

Sandostatin LAR Depot (octreotide acetate for injectable suspension)

Drug company: Novartis
877-503-3377

Sandostatin LAR is a somatostatin analog used for the long-term treatment of patients with severe diarrhea or flushing episodes associated with metastatic carcinoid tumors.

Novartis’ Patient Assistance NOW Oncology provides 2 financial assistance programs for patients using Sandostatin LAR Depot:

Sandostatin LAR Depot Co-Pay Assistance Program

Patients with private insurance will pay up to $25 per month in copay and coinsurance. The program pays the remaining balance for Sandostatin LAR Depot until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients with limited or no public or private insurance may be able to receive Sandostatin LAR Depot for free. The patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person and up to $25,000 more for each additional person. Eligible patients will receive Sandostatin LAR Depot for free for 1 year, or until they have prescription drug coverage.

Somatuline Depot (lanreotide) Injection

Drug company: Ipsen
866-435-5677

Somatuline Depot is a somatostatin analog used for the treatment of adults with carcinoid syndrome, and reduces the frequency of short-acting somatostatin analog rescue therapy.

IPSEN CARES offers 2 financial assistance programs for patients using Somatuline Depot:

IPSEN CARES offers 2 financial assistance programs for patients using Somatuline Depot:

Eligible patients with private insurance pay no more than $5 per prescription with this program for 12 months, 13 injections, or for a maximum copay benefit of $20,000 (whichever comes first). Patients with no insurance, or those whose insurance does not cover Somatuline Depot, may pay more than $5 per prescription and their maximum copay benefit amount for prescriptions is $1,666.66, up to an annual maximum of $20,000.

Somatuline Depot Patient Assistance Program

Eligible patients who are experiencing financial hardship, or who have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.

Xermelo (telotristat ethyl) Tablets

Drug Company: Lexicon
844-937-6356

Xermelo is a tryptophan hydroxylase inhibitor used for the treatment of patients with carcinoid syndrome diarrhea, in combination with a somatostatin analog, in adults whose disease is inadequately controlled by somatostatin analog therapy.

Lexicon’s LexCares offers 2 financial assistance programs for patients using Xermelo:

LexCares $0 Co-pay

For patients with private insurance, LexCares provides Xermelo with a $0 copay and up to $10,000 annually.

Lexicon Patient Assistance Program

For patients who have Medicare or Medicaid coverage or have no insurance, and who also meet certain financial criteria, the LexCares specialty pharmacy partners will help to identify an appropriate patient assistance program.

Table. Drugs Prescribed for Neuroendocrine Tumors (NETs)

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services



Carcinoid Syndrome
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Xermelo (telotristat ethyl) Tablets
  • Drug company
  • Lexicon
  • Indication
  • Carcinoid syndrome diarrhea, in combination with a somatostatin analog
  • Patient support services
  • LexCares $0 Co-pay
    844-937-6356

    Lexicon Patient Assistance Program
    844-937-6356

Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here